Clinical Trial Update: Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC [Phase 2]

View source ↗

Summary

This document outlines a Phase 2 trial evaluating preoperative pembrolizumab in combination with chemotherapy for resectable and recurrent head and neck squamou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Status: RECRUITING